Reducing the costs of phase III cardiovascular clinical trials

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 482-488

  Eisenstein, Eric L ^a,d   Lemons II, Philip W ^a   Tardiff, Barbara E ^b   Schulman, Kevin A ^a   Jolly, M King ^c   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c King Pharmaceuticals   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; TRANDOLAPRIL;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG INDUSTRY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HUMAN; MATHEMATICAL MODEL; MEDICAL EXPERT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

EID: 17844363698     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.04.049     Document Type: Article

References (19)

1. PhRMA Annual Report 2000-2001. Washington, DC: Pharmaceutical Research and Manufacturers of America; 2001.
2. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price o innovation: new estimates o drug develoment costs J Health Econ 22 2003 151 185
3. S.O. Schweitzer Pharmaceutical economics and policy 1997 Oxford University Press New York
4. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Parts 1 and 2. Circulation 2002;106:746-51, 880-5.
5. S. Yusuf, R. Collins, and R. Peto Why do we need some large, simple randomized trials? Stat. Med. 3 1984 409 420
6. T.R. Fleming, and D.L. DeMets Surrogate endpoints in clinical trials: are we being misled? Ann. Intern. Med. 125 1996 605 613
7. E.J. Topol, R.M. Califf, and F. Van de Werf Perspectives on large-scale cardiovascular clinical trials for the new millennium Circulation 95 1997 1072 1082
8. J.C. Wright, and M.C. Weinstein Gains in life expectancy from medical interventions-standardizing data on outcomes N. Engl. J. Med. 339 1998 380 386
9. M.A. Pfeffer, E. Braunwald, and L.A. Moye Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement (SAVE) trial N. Engl. J. Med. 327 1992 669 677
10. J.G. Cleland, L. Erhardt, and G. Murray Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators Eur. Heart J. 18 1997 41 51
11. L. Kober, C. Torp-Pedersen, and J.E. Carlsen A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 333 2000 1670 1676
12. A.S. Detsky Using cost-effectiveness analysis to improve the efficiency of allocating funds to clinical trials Stat. Med. 9 1990 173 184
13. R.L. Prentice Opportunities for enhancing efficiency and reducing costs in large scale disease prevention trials: a statistical perspective Stat. Med. 9 1990 161 170
14. M.D. Thornquist, N. Urgan, and A. Tseng Research cost analysis to aid in decision making in the conduct of a large prevention trial. CARET Control Clin. Trials 14 1993 325 339
15. N. Urgan, S. Self, and L. Kessler Analysis of the costs of a large prevention trial Control Clin. Trials. 11 1990 129 146
16. M.D. Heller, and J.A. Boyle Clinical research opportunities: a physician's guide to participating in clinical research studies 1996 Practice Management Information Corp. Los Angeles
17. D.J. McEntegart, S.P. Jadhav, and T. Brown Checks of case record forms versus the database for efficacy variables when validation programs exist Drug Inf. J. 33 1999 101 107
18. R.B. Weiss, N.J. Vogelzang, and B.A. Peterson A successful system of scientific data audits for clinical trials: a report from the Cancer and Leukemia Group JAMA 270 1993 459 464
19. R.M. Califf, S.L. Karnash, and L.H. Woodlief Developing systems for cost-effective auditing of clinical trials Control Clin. Trials 18 1997 651 660